ArticleBioinformatics (Oxford, England)2026
Harmonization and integration of pharmacogenomics screens.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
motivationLarge pharmacogenomics screens have generated a wealth of information cataloguing the responses of more than a thousand tumor cell-line models to FDA-approved and exploratory drugs. Although centralized repositories have consolidated data access, the diversity of experimental platforms and response metrics used in these screens have made it challenging to integrate and compare their measured drug responses. Towards better pharmacogenomic data harmonization, we surveyed a range of data analysis protocols based on different curve-fitting functions (sigmoid, piecewise linear), different response metrics (IC50, EC50, integrated AUC), and different drug concentration windows (full range or truncated).
resultsWe found that an AUC derived from a sigmoidal curve fitted to a truncated dose range yields the strongest agreement between screening platforms, significantly bettering other protocols surveyed. This harmonization procedure also best aligns drug responses across successive iterations of the same platform. These findings broadly inform efforts to integrate drug response data in large-scale analyses. AVAILABILITY: The source code to generate drug response profiles and correlations are available at https://github.com/digitaltumors/Pharmacogenomics_Screens_Harmonization.git.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.